Immunotherapy and Advanced Vulvar Cancer: A Systematic Review and Meta-Analysis of Survival and Safety Outcomes.

A subgroup analysis comparing single-agent versus combination regimens (Yeku et al., SWOG S1609; n = 40) found a higher ORR with combination therapy (46%, 95% CI: 0–100%, I 2 = 90.4%) versus monotherapy (11%, 95% CI: 5–22%, I 2 = 0%), although the difference did not reach statistical significance ( p = 0.13), indicating a possible but not statistically confirmed difference in efficacy between single-agent and combination strategies [ 39 , 40 ] ( Figure 4 ).

also in 111,027 other papers